The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects

• Published in: Psychopharmacologia Vol. 185; no. 1; pp. 11 - 18
• Main Authors: Cohrs, Stefan, Röher, Cornelia, Jordan, Wolfgang, Meier, Andreas, Huether, Gerald, Wuttke, Wolfgang, Rüther, Eckart, Rodenbeck, Andrea
• Format: Journal Article
• Language: English
• Published: Berlin Springer 01.03.2006; Springer Nature B.V
• Subjects: Adrenocorticotropic Hormone - blood; Adult; Antipsychotic Agents - pharmacology; Antipsychotics; Benzodiazepines - pharmacology; Biological and medical sciences; Cross-Over Studies; Dibenzothiazepines - pharmacology; Double-Blind Method; Haloperidol - pharmacology; Humans; Hydrocortisone - blood; Hypothalamo-Hypophyseal System - drug effects; Male; Medical sciences; Neuropharmacology; Pharmacology. Drug treatments; Pituitary-Adrenal System - drug effects; Prolactin - blood; Psycholeptics: tranquillizer, neuroleptic; Psychology. Psychoanalysis. Psychiatry; Psychopharmacology; Quetiapine Fumarate; Atypical antipsychotic; Olanzapine; Neuroleptic; Psychotropic; Serotonine receptor; Haloperidol; Hydrocortisone; Glucocorticoid; Dibenzothiazepine derivatives; Quetiapine; Human; Corticosteroid; Healthy subject; Steroid hormone; Secretion; Dopamine antagonist; Serotonin antagonist; Hypnotic; Butyrophenone derivatives; Thienobenzodiazepine derivatives; Chemotherapy; D2 Dopamine receptor; Adrenocorticotropic hormone; Tranquillizer; Adenohypophyseal hormone; Adrenal hormone

Increased activity of the hypothalamic-pituitary-adrenal (HPA) axis is an important aspect of the pathophysiology of major depression and schizophrenia. Despite the usefulness of atypical antipsychotics in the treatment of depression and their positive influence on cognitive functioning possibly rel...